Dare Bioscience, Inc. Common Stock
Here’s whether Dare Bioscience, Inc. Common Stock (DARE) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-9.79% over 10 days); weak 1-year return of -55.1%; 3-month momentum negative (-57.1%); rising volume on a downtrend (distribution, 2.39x avg). Currently 75.4% off its 52-week high. Score: -6/7.
DARE is trading below its 200-day MA ($1.90) — a key warning sign the longer-term trend is under pressure. An RSI of 32.1 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -55.1% compares to +20.4% for SPY (trailed the market by 75.4%). The current 75.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.